Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2010 2
2011 1
2013 1
2014 1
2016 1
2017 1
2018 1
2019 3
2020 1
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Establishment of In Vivo Acquired Resistance to Chemotherapy Via Individual Dose Escalation Treatment Regime.
Barker KT, Yogev O. Barker KT, et al. Among authors: yogev o. Methods Mol Biol. 2022;2535:73-83. doi: 10.1007/978-1-0716-2513-2_6. Methods Mol Biol. 2022. PMID: 35867223
The vast majority of cancer deaths are the result of drug resistance. The lack of superior preclinical models that better reflect the complexity of relapsed disease hinders the development of novel therapeutics. 2D and 3D in vitro cell-based assays have provided some infor …
The vast majority of cancer deaths are the result of drug resistance. The lack of superior preclinical models that better reflect the …
Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma.
Nijhuis A, Sikka A, Yogev O, Herendi L, Balcells C, Ma Y, Poon E, Eckold C, Valbuena GN, Xu Y, Liu Y, da Costa BM, Gruet M, Wickremesinghe C, Benito A, Kramer H, Montoya A, Carling D, Want EJ, Jamin Y, Chesler L, Keun HC. Nijhuis A, et al. Among authors: yogev o. Nat Commun. 2022 Mar 16;13(1):1380. doi: 10.1038/s41467-022-28907-3. Nat Commun. 2022. PMID: 35296644 Free PMC article.
The Metabolic Profile of Tumor and Virally Infected Cells Shapes Their Microenvironment Counteracting T Cell Immunity.
Magalhaes I, Yogev O, Mattsson J, Schurich A. Magalhaes I, et al. Among authors: yogev o. Front Immunol. 2019 Oct 4;10:2309. doi: 10.3389/fimmu.2019.02309. eCollection 2019. Front Immunol. 2019. PMID: 31636636 Free PMC article. Review.
It has long been appreciated that the conversion of a healthy cell to a cancerous cell is accompanied by metabolic changes, which support uncontrolled proliferation. ...
It has long been appreciated that the conversion of a healthy cell to a cancerous cell is accompanied by metabolic changes, which sup …
Redefining KSHV latency.
Yogev O, Boshoff C. Yogev O, et al. Cell Host Microbe. 2013 Apr 17;13(4):373-4. doi: 10.1016/j.chom.2013.04.003. Cell Host Microbe. 2013. PMID: 23601098 Free article.
Genome wide screen of RNAi molecules against SARS-CoV-2 creates a broadly potent prophylaxis.
Yogev O, Weissbrod O, Battistoni G, Bressan D, Naamti A, Falciatori I, Berkyurek AC, Rasnic R, Hosmillo M, Ilan S, Grossman I, McCormick L, Honeycutt CC, Johnston T, Gagne M, Douek DC, Goodfellow I, Hannon GJ, Erlich Y. Yogev O, et al. bioRxiv [Preprint]. 2022 Apr 12:2022.04.12.488010. doi: 10.1101/2022.04.12.488010. bioRxiv. 2022. PMID: 35441162 Free PMC article. Updated. Preprint.
Noncoding RNAs and cancer.
Yogev O, Lagos D. Yogev O, et al. Silence. 2011 Sep 29;2(1):6. doi: 10.1186/1758-907X-2-6. Silence. 2011. PMID: 21958754 Free PMC article.
The study of miRNAs and other noncoding RNAs has revolutionised our understanding of gene expression regulation during cancer development and progression, creating one of the fastest-growing research fields in cancer with realistic therapeutic potential. The 2011 No …
The study of miRNAs and other noncoding RNAs has revolutionised our understanding of gene expression regulation during cancer develop …
From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis.
Yogev O, Weissbrod O, Battistoni G, Bressan D, Naamati A, Falciatori I, Berkyurek AC, Rasnic R, Izuagbe R, Hosmillo M, Ilan S, Grossman I, McCormick L, Honeycutt CC, Johnston T, Gagne M, Douek DC, Goodfellow I, Hannon GJ, Erlich Y. Yogev O, et al. Commun Biol. 2023 Mar 16;6(1):277. doi: 10.1038/s42003-023-04589-5. Commun Biol. 2023. PMID: 36928598 Free PMC article.
In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis.
Yogev O, Almeida GS, Barker KT, George SL, Kwok C, Campbell J, Zarowiecki M, Kleftogiannis D, Smith LM, Hallsworth A, Berry P, Möcklinghoff T, Webber HT, Danielson LS, Buttery B, Calton EA, da Costa BM, Poon E, Jamin Y, Lise S, Veal GJ, Sebire N, Robinson SP, Anderson J, Chesler L. Yogev O, et al. Cancer Res. 2019 Oct 15;79(20):5382-5393. doi: 10.1158/0008-5472.CAN-18-2759. Epub 2019 Aug 12. Cancer Res. 2019. PMID: 31405846
Neuroblastoma is a pediatric cancer that is frequently metastatic and resistant to conventional treatment. ...
Neuroblastoma is a pediatric cancer that is frequently metastatic and resistant to conventional treatment. ...
Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.
Fultang L, Gamble LD, Gneo L, Berry AM, Egan SA, De Bie F, Yogev O, Eden GL, Booth S, Brownhill S, Vardon A, McConville CM, Cheng PN, Norris MD, Etchevers HC, Murray J, Ziegler DS, Chesler L, Schmidt R, Burchill SA, Haber M, De Santo C, Mussai F. Fultang L, et al. Among authors: yogev o. Cancer Res. 2019 Feb 1;79(3):611-624. doi: 10.1158/0008-5472.CAN-18-2139. Epub 2018 Dec 13. Cancer Res. 2019. PMID: 30545920 Free PMC article.
p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.
Yogev O, Barker K, Sikka A, Almeida GS, Hallsworth A, Smith LM, Jamin Y, Ruddle R, Koers A, Webber HT, Raynaud FI, Popov S, Jones C, Petrie K, Robinson SP, Keun HC, Chesler L. Yogev O, et al. Cancer Res. 2016 May 15;76(10):3025-35. doi: 10.1158/0008-5472.CAN-15-1939. Epub 2016 Mar 29. Cancer Res. 2016. PMID: 27197232 Free article.
Our findings highlight the complex pathways operating in relapsed neuroblastomas and the need for combination therapies that target the diverse resistance mechanisms at play. Cancer Res; 76(10); 3025-35. 2016 AACR....
Our findings highlight the complex pathways operating in relapsed neuroblastomas and the need for combination therapies that target the dive …
17 results